Rare Pediatric Disease Priority Review Vouchers

The New Drug Approval Process: NDA Submission and Review

– Priority Review (PDUFA) • For serious conditions and demonstrated potential for significant improvement in safety or effectiveness • Also available to sponsors that redeem priority review vouchers (tropical disease, rare pediatric disease, medical countermeasure priority review vouchers, FDCA §§ 524, 529, 565A )

  Review, Disease, Pediatric, Rear, Priority, Voucher, Priority review, Priority review vouchers, Rare pediatric disease